美沙拉嗪联合益生菌治疗溃疡性结肠炎的疗效分析

Therapeutic Effect of Mesalazine Combined with Probiotics on Ulcerative Colitis

目的观察探究美沙拉嗪联合益生菌治疗溃疡性结肠炎的临床疗效。方法该次药物研究中被研究者为方便选取60例自2017年1月—2018年1月间与该院诊疗过的溃疡性结肠炎患者,对选出的患者进行编号,编号为1～30号的30例患者为联合用药组(患者采用美沙拉嗪联合益生菌的方法治疗),编号为31～60号的30例患者为比对组(患者仅用美沙拉嗪进行治疗),比较两组疗效。结果联合用药组患者60 d治疗结束后,治疗总有效率为93.3%,比对组为73.3%,前者治疗总有效率显著高于后者,差异有统计学意义(χ~2=4.320 0,P=0.037 6,P<0.05),实施用药治疗措施前,两组患者临床症状比较差异无统计学意义(P>0.05),治疗后,患者症状均得到改善,其中联合用药组患者腹痛血性腹泻、里急后重以及黏液便症状改善情况显著优于比对组患者,差异有统计学意义(χ~2=5.710 9,5.192 3,4.811 8,P=0.016 8,0.022 6,0.028 2,P<0.05),联合用药组不良反应发生率为13.3%,比对组为10.0%,两组不良反应发生率比较差异无统计学意义(χ~2=0.161 7,P=0.687 5),联合用药组复发率为6.7%远低于比对组的30.0%,差异有统计学意义(χ~2=5.454 5,P=0.019 5,P<0.05)。结论采用美沙拉嗪联合益生菌的联合用药方法对溃疡性结肠炎患者进行治疗,效果要好于单纯使用美沙拉嗪进行治疗的患者,且联合用药治疗方法复发率低,因此值得临床使用。

Objective To observe the clinical efficacy of mesalazine combined with probiotics in the treatment of ulcerative colitis.Methods The study was conducted in 60 patients with ulcerative colitis who were treated in the hospital from January 2017 to January 2018.The convenient selected patients were numbered from 1-30.Thirty patients were treated in a combination group(patients treated with mesalazine in combination with probiotics),and 30 patients numbered 31-60 were in the comparison group(patients were treated with mesalazine only),comparing two group efficacy.Results After 60 days of treatment,the total effective rate was 93.3%in the combination group and 73.3%in the comparison group.The total effective rate of the former was significantly higher than that of the latter(χ^2=4.320 0,P=0.037 6,P<0.05),before the implementation of medication treatment,there was no difference in clinical symptoms between the two groups(P >0.05).After treatment,the symptoms of the patients were improved.Among them,the patients in the combination group had obvious improvement in abdominal pain,bloody diarrhea,urgency,and mucus symptoms.In the comparison group,the difference was significant(χ^2=5.710 9,5.192 3,4.811 8,P=0.016 8,0.022 6,0.028 2,P<0.05).The incidence of adverse reactions was 13.3%in the combination group and 10.0%in the comparison group.There was no difference in the incidence of reaction(χ^2=0.161 7,P=0.687 5).The recurrence rate was 6.7%in the combination group and 30.0%in the comparison group(χ^2=5.454 5,P=0.019 5,P<0.05).Conclusion The combination of mesalazine and probiotics for the treatment of patients with ulcerative colitis is better than patients treated with mesalamine alone,and the combined treatment has a low recurrence rate,so it is worthy of clinical use.